Kenjockety Biotechnology addresses the unmet need of drug resistance in cancer patients by developing a new family of bispecific antibodies. Their proprietary BASE™ Platform pairs foundational antibodies targeting Efflux Pumps (EPs) with antibodies to known Tumor Associated Antigen (TAA) targets, creating bispecific antibodies that effectively target tumor cells. Unlike previous attempts using small molecules, Kenjockety's approach focuses on highly specific BsAbs engineered for cancer cells. Impressive in vivo proof of concept data demonstrates efficacy across multiple tumor models, showing potential for both single agent and combination therapies. With evidence of drug resistance due to EP overexpression in various solid tumors and hematologic malignancies, Kenjockety aims to advance their pipeline by conducting in vivo testing for multiple new BsAbs. Key milestones include selecting a lead product candidate and completing IND enabling studies for clinical trials.